SARA SEXSON TEJTEL to Immunoglobulins, Intravenous
This is a "connection" page, showing publications SARA SEXSON TEJTEL has written about Immunoglobulins, Intravenous.
Connection Strength
0.522
-
Infliximab versus second intravenous immunoglobulin for treatment of resistant Kawasaki disease in the USA (KIDCARE): a randomised, multicentre comparative effectiveness trial. Lancet Child Adolesc Health. 2021 12; 5(12):852-861.
Score: 0.176
-
Variability in Kawasaki Disease Practice Patterns: A Survey of Hospitalists at Pediatric Hospital Medicine 2017. Hosp Pediatr. 2019 09; 9(9):724-728.
Score: 0.151
-
The Kawasaki Disease Comparative Effectiveness (KIDCARE) trial: A phase III, randomized trial of second intravenous immunoglobulin versus infliximab for resistant Kawasaki disease. Contemp Clin Trials. 2019 04; 79:98-103.
Score: 0.146
-
Variation in Early Anakinra Use and Short-Term Outcomes in Multisystem Inflammatory Syndrome in Children. Arthritis Rheumatol. 2023 08; 75(8):1466-1476.
Score: 0.049